These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 30713036)
21. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555 [TBL] [Abstract][Full Text] [Related]
22. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150 [TBL] [Abstract][Full Text] [Related]
23. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. Karakiewicz PI; Bhojani N; Neugut A; Shariat SF; Jeldres C; Graefen M; Perrotte P; Peloquin F; Kattan MW J Sex Med; 2008 Apr; 5(4):919-927. PubMed ID: 18371045 [TBL] [Abstract][Full Text] [Related]
24. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261 [TBL] [Abstract][Full Text] [Related]
25. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy. Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975 [TBL] [Abstract][Full Text] [Related]
26. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Duchesne GM; Woo HH; King M; Bowe SJ; Stockler MR; Ames A; D'Este C; Frydenberg M; Loblaw A; Malone S; Millar J; Tai KH; Turner S Lancet Oncol; 2017 Sep; 18(9):1192-1201. PubMed ID: 28760403 [TBL] [Abstract][Full Text] [Related]
27. Quality of life three years after diagnosis of localised prostate cancer: population based cohort study. Smith DP; King MT; Egger S; Berry MP; Stricker PD; Cozzi P; Ward J; O'Connell DL; Armstrong BK BMJ; 2009 Nov; 339():b4817. PubMed ID: 19945997 [TBL] [Abstract][Full Text] [Related]
28. Stability of health-related quality of life and morbidity burden from 18 months after diagnosis of prostate cancer: results of a UK-wide population-based outcome cohort. Mason SJ; Downing A; Wilding S; Hounsome L; Wright P; Watson E; Wagland R; Butcher H; Kind P; Selby P; Gavin A; Glaser AW Support Care Cancer; 2022 Apr; 30(4):3151-3164. PubMed ID: 34904181 [TBL] [Abstract][Full Text] [Related]
29. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Lubeck DP; Grossfeld GD; Carroll PR Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459 [TBL] [Abstract][Full Text] [Related]
30. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial. Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431 [TBL] [Abstract][Full Text] [Related]
31. Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study. Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y Eur J Cancer; 2016 Sep; 65():43-51. PubMed ID: 27459586 [TBL] [Abstract][Full Text] [Related]
32. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763 [TBL] [Abstract][Full Text] [Related]
33. Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study. Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A Radiother Oncol; 2021 Feb; 155():48-55. PubMed ID: 33075390 [TBL] [Abstract][Full Text] [Related]
34. Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry. Bensley JG; Dhillon HM; Evans SM; Evans M; Bolton D; Davis ID; Dodds L; Frydenberg M; Kearns P; Lawrentschuk N; Murphy DG; Millar JL; Papa N Psychooncology; 2022 Mar; 31(3):496-503. PubMed ID: 34623735 [TBL] [Abstract][Full Text] [Related]
35. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Kato T; Komiya A; Suzuki H; Imamoto T; Ueda T; Ichikawa T Int J Urol; 2007 May; 14(5):416-21. PubMed ID: 17511724 [TBL] [Abstract][Full Text] [Related]
36. Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. Wagner AA; Cheng PJ; Carneiro A; Dovirak O; Khosla A; Taylor KN; Crociani CM; McAnally KC; Percy A; Dewey LE; Sanda MG; Chang P J Urol; 2017 Jan; 197(1):109-114. PubMed ID: 27475967 [TBL] [Abstract][Full Text] [Related]
37. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. Kyrdalen AE; Dahl AA; Hernes E; Småstuen MC; Fosså SD BJU Int; 2013 Feb; 111(2):221-32. PubMed ID: 22672151 [TBL] [Abstract][Full Text] [Related]
38. Population-based study of long-term functional outcomes after prostate cancer treatment. Carlsson S; Drevin L; Loeb S; Widmark A; Lissbrant IF; Robinson D; Johansson E; Stattin P; Fransson P BJU Int; 2016 Jun; 117(6B):E36-45. PubMed ID: 25959859 [TBL] [Abstract][Full Text] [Related]
39. Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients. Venderbos LDF; Deschamps A; Dowling J; Carl EG; Remmers S; van Poppel H; Roobol MJ Eur Urol Focus; 2021 Sep; 7(5):987-994. PubMed ID: 33281109 [TBL] [Abstract][Full Text] [Related]
40. Quality of life in prostate cancer patients taking androgen deprivation therapy. Dacal K; Sereika SM; Greenspan SL J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]